NSF International Acquires Auditing Arm of IPEC-Americas

News
Article

NSF-IPEA now can provide excipient auditing and certification.

NSF International, a public health organization, has acquired the auditing subsidiary of the International Pharmaceutical Excipients Council of the Americas (IPEC-Americas): IPEA. As a result of the acquisition, NSF-IPEA now can provide excipient auditing and certification as part of NSF’s Health Sciences Pharma Biotech Division and clients can also obtain bundled excipient, food additive, and dietary supplement ingredient audits from NSF.

As the only excipient GMP certification program accredited by the American National Standards Institute, NSF-IPEA offers third-party audits based on IPEC – PQG GMP Guide for pharmaceutical excipients and excipient GMP certification, the organization reports.

NSF International is working with representatives from the chemical and pharma industries and FDA staff to develop an NSF/ANSI excipient GMP consensus standard. The standard, expected to be completed this year, defines GMPs for excipient manufacture for use in drug products and specifies the components of a quality management system for excipient manufacture.

NSF Health Sciences Pharma Biotech Vice President Janeen Skutnik-Wilkinson, will lead the excipients program. Skutnik-Wilkinson has 20 years of experience in technical and regulatory support roles for the pharmaceutical industry including leadership positions with Pfizer, Merck, and IPEC.

The IPEA program auditors will remain and additional auditors will be trained and certified by the International Register of Certificated Auditors. The certification board and the procedures will remain as they were under IPEC-Americas.

Source: NSF International

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.